CytomX Therapeutics, Inc. (CTMX): Revenue
$76.20M
Year ended 2025-12-31
$18.30M
Trailing 12 months to 2026-06-30
+12.8%
3-year compound annual growth
+2.2%
5-year compound annual growth
+25.7%
10-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $76.20M | -44.8% | 2026-03-16, From 2025-01-01 |
| 2024-12-31 | $138.10M | +36.4% | 2026-03-16, From 2024-01-01 |
| 2023-12-31 | $101.21M | +90.4% | 2025-03-06, From 2023-01-01 |
| 2022-12-31 | $53.16M | +42.5% | 2024-03-11, From 2022-01-01 |
| 2021-12-31 | $37.31M | -45.5% | 2023-03-27, From 2021-01-01 |
| 2020-12-31 | $68.43M | +154.4% | 2023-03-27, From 2020-01-01 |
| 2019-12-31 | $26.90M | -54.8% | 2023-03-27, From 2019-01-01 |
| 2018-12-31 | $59.50M | -16.9% | 2021-02-24, From 2018-01-01 |
| 2017-12-31 | $71.62M | +376.1% | 2020-02-27, From 2017-01-01 |
| 2016-12-31 | $15.04M | +95.1% | 2019-02-27, From 2016-01-01 |
| 2015-12-31 | $7.71M | +51.9% | 2018-03-07, From 2015-01-01 |
| 2014-12-31 | $5.08M | +471.7% | 2017-03-02, From 2014-01-01 |
| 2013-12-31 | $888.0K | n/a | 2016-03-07, From 2013-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | 2025-12-31 | $76.20M | -44.8% |
| AbCellera Biologics Inc. (ABCL) | 2025-12-31 | $75.13M | +160.6% |
| Eton Pharmaceuticals, Inc. (ETON) | 2025-12-31 | $79.95M | +104.9% |
| Bicycle Therapeutics PLC (BCYC) | 2025-12-31 | $72.59M | +105.8% |
| Assembly Biosciences, Inc. (ASMB) | 2025-12-31 | $72.30M | +153.5% |
| ADC Therapeutics SA (ADCT) | 2025-12-31 | $81.36M | +14.9% |
| Viridian Therapeutics, Inc. (VRDN) | 2025-12-31 | $70.85M | n/m |
| Arcturus Therapeutics Holdings Inc. (ARCT) | 2025-12-31 | $82.03M | -46.1% |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | $69.26M | -31.8% |
Compare CTMX, ABCL, ETON, BCYC side by side · Screen every company in Pharmaceutical Preparations ↗